NasdaqGS:LEGNBiotechs
Legend Biotech (NasdaqGS:LEGN): Assessing Valuation After Strong Results and New Philadelphia R&D Launch
Legend Biotech's latest quarterly report highlights a sharp jump in revenue and a much smaller net loss compared to last year, signaling real traction in its cell therapy business. At the same time, the company just opened a new research and development facility in Philadelphia, which further strengthens its position in oncology and immunology.
See our latest analysis for Legend Biotech.
Legend Biotech’s momentum has shifted this year, with its expanded R&D efforts and stronger revenue...